Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.
X-Chem announced a collaboration with Vertex for the discovery of small-molecule leads against validated targets for severe, genetic diseases.
Espero Pharmaceuticals – a commercial-stage cardiovascular pharma company – and Armetheon – a late-clinical stage pharma company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases – plan to merge.
Habit and red tape are not sufficient excuses for life sciences organizations to keep doing things the way they always have.
Advanced R&D, Manufacturing, and Packaging Facility to Serve as U.S. Headquarters; Initially Expected to Create Minimum of 150 Full-Time Jobs BROWARD COUNTY, Fla., March 8, 2017 /PRNewswire/ — Today Apotex […]
March 8, 2017 By Mark Terry, BioSpace.com Breaking News Staff Waltham, Mass.-based XTuit Pharmaceuticals announced today that Deborah Dunsire was stepping in as president, chief executive officer, and board member. […]
Pfizer has its eyes set on a possible $100 million investment to expand a plant in Sanford, N.C. with a focus on gene therapy, according to the Triangle Business Journal. The investment would include the addition of 50 new jobs.
For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.
Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai
Despite the general anxiety over the impact of President Trump’s policies, when it comes to pharmaceutical sales forces, little of what he does will actually affect pharma sales-force strategies. The trends that are continuing to play out are declining rep access, the size of pharma sales forces, and the struggle with the concept of key account management, as well as trying to figure out how reps should be compensated.
